 therapy (including
statins) is equivalent or superior to CEA or CAS has not
yet been addressed by well-designed, appropriately
funded, prospective, multicenter, and randomized trials.
However, when the stroke rate of the patients receiving
lipid-lowering medication in the ACST trial was analyzed,
the patients who had undergone CEA with lipid-lowering
medication had a lower stroke incidence compared with
the medical therapy arm. However, the effect of CEA was
